Efficacy and Safety of Xience in Coronary arEry Disease aLL-comers After stENTing Using the PRIME Platform (EXCELLENT-PRIME Registry)

Overview

Objectives: 1. To evaluate the safety and long-term effectiveness of coronary stenting with the XIENCE PRIMETM in a cohort of "real world" patients and lesion subsets. 2. To determine clinical device and procedural success during commercial use of XIENCE PRIMETM coronary stent Study population : Approximately consecutive 2000 patients treated with XIENCE PRIMETM Study period * Patient enrollment: 2011.05 \~ 2012.04 * End of follow-up period: 2015. 02 (3 years of follow-up) Primary endpoint : Target Lesion Failure (TLF) rate at 12 months Secondary endpoint: * In-stent \& In-segment Late Loss at 9 months * Stent Thrombosis at 24 hours (acute), 30 days (subacute), 1 year (late), yearly up to 3 years (very late) * Target Vessel Failure at 12 months (composite of cardiac death, MI, and TVR) * Any death, cardiac death, MI, TLR, TVR at 30 days, 9months, 1 year, 3 years * Composite rate of cardiac death and any MI up to 3 years * Composite rate of all death and any MI up to 3 years * Composite rate of all death, any MI (Q-wave and non Q-wave) and any repeat revascularization up to 3 years * Compliance and therapy interruptions with prescribed adjunctive antiplatelet therapy up to 3 years * Procedural success up to 1 day * Angiographic success up to 1 day

Conditions